Belanoff Maintains 6.58M Share Stake in Corcept Therapeutics

TL;DR

**Insider Joseph K. Belanoff still holds over 6.5 million shares of CORT.**

AI Summary

Joseph K. Belanoff, a key individual associated with Corcept Therapeutics Inc. (CORT), filed an SC 13G/A on February 12, 2024, updating his beneficial ownership as of December 31, 2023. He reported sole voting and dispositive power over 6,581,918 shares of Common Stock. This filing, an amendment to previous disclosures, indicates a stable or slightly adjusted significant insider holding, which can signal confidence in the company's future to investors.

Why It Matters

This filing shows that a significant insider, Joseph K. Belanoff, continues to hold a substantial stake in Corcept Therapeutics, which can be interpreted by investors as a sign of his continued belief in the company's prospects.

Risk Assessment

Risk Level: low — This filing is an amendment to an existing disclosure and indicates a stable insider holding, posing minimal new risk.

Analyst Insight

Investors should note the continued significant insider holding by Joseph K. Belanoff, which could be a positive signal of long-term confidence in Corcept Therapeutics. However, this filing itself doesn't indicate new buying or selling activity, so further analysis of other filings or company news would be prudent.

Key Numbers

• 6,581,918 — Shares Beneficially Owned (Represents the total number of Corcept Therapeutics Common Stock shares Joseph K. Belanoff has sole voting and dispositive power over as of December 31, 2023.)

Key Players & Entities

• Joseph K. Belanoff (person) — Reporting Person, likely an executive or director of Corcept Therapeutics Inc.
• Corcept Therapeutics Incorporated (company) — The issuer of the securities being reported on.
• 6,581,918 (dollar_amount) — Number of shares beneficially owned by Joseph K. Belanoff.

Forward-Looking Statements

• Joseph K. Belanoff will maintain a significant ownership stake in Corcept Therapeutics Inc. for the foreseeable future. (Joseph K. Belanoff) — medium confidence, target: December 31, 2024

FAQ

Key Financial Figures

• $0.001 — f Securities: Common stock, par value $0.001 per share (Common Stock). (e) CUSIP

Filing Documents

• d763510dsc13ga.htm (SC 13G/A) — 36KB
• 0001193125-24-032468.txt ( ) — 37KB

From the Filing

SC 13G/A 1 d763510dsc13ga.htm SC 13G/A SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Corcept Therapeutics Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 218352102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 218352102 Schedule 13G Page 2 of 5 1 Names of Reporting Persons Joseph K. Belanoff 2 Check the Appropriate Box if a Member of a Group (a) (b) 3 SEC Use Only 4 Citizenship or Place of Organization United States Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 6,581,918 6 Shared Voting Power 0 7 Sole Dispositive Power 6,581,918 8 Shared Dispositive Power 0 9 Aggregate Amount Beneficially Owned by Each Reporting Person 6,581,918 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares Not Applicable 11 Percent of Class Represented by Amount in Row 9 6.1% 12 Type of Reporting Person IN CUSIP No. 218352102 Schedule 13G Page 3 of 5 ITEM1. (a) Name of Issuer: Corcept Therapeutics Incorporated (the Issuer). (b) Address of Issuers Principal Executive Offices: 149 Commonwealth Drive Menlo Park, CA 94025 ITEM2. (a) Name of Person Filing: This statement is filed on behalf of Dr. Joseph K. Belanoff (the Reporting Person). (b) Address or Principal Business Office: The business address of the Reporting Person is c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, CA 94025. (c) Citizenship of each Reporting Person is: The Reporting Person is a citizen of the United States. (d) Title of Class of Securities: Common stock, par value $0.001 per share (Common Stock). (e) CUSIP Number: 218352102 ITEM3. Not applicable. CUSIP No. 218352102 Schedule 13G Page 4 of 5 ITEM4. The ownership information below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2023, based upon 107,155,403 shares of Common Stock outstanding as of December 31, 2023. (a) Amount beneficially owned: The Reporting Person beneficially owns 6,581,918 shares of Common Stock, which consist of (i) 2,831,918 shares of Common Stock and (ii) 3,750,000 shares of Common Stock underlying stock options that are exercisable prior to March 1, 2024. (b) Percent of class: 6.1% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 6,581,918 (ii) Shared power to vote or direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 6,581,918 (iv) Shared power to dispose or to direct the disposition of: 0 ITEM5. Not applicable. ITEM6. Not applicable. ITEM7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not applicable. ITEM8. Identification and Classification of Members of the Group. Not applicable. ITEM9. Notice of Dissolution of Group. Not applicable. ITEM10. Certification. Not applicable. CUSIP No. 218352102 Schedule 13G Page 5 of 5 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : February 12, 2024 /s/ Joseph K. Belanoff

View Full Filing

View this SC 13G/A filing on SEC EDGAR